Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibrompropamidine SCHEMBL292947 | 1.00 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL21083095 | 0.98 | F2 (0.97) | F2PLAUST14PRSS1 | |
| SCHEMBL597315 | 0.95 | F2 (0.90) | F2PLAUST14PRSS1 | |
| SCHEMBL14599538 | 0.95 | F2 (0.90) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL28086367 | 0.92 | F2 (0.85) | F2PLAUST14PRSS1 | |
| SCHEMBL16360744 | 0.89 | F2 (0.79) | F2PLAUST14PRSS1 | |
| SCHEMBL22824438 | 0.88 | F2 (0.78) | F2PLAUST14PRSS1 | |
| SCHEMBL1428334 | 0.88 | F2 (0.78) | F2PLAUST14PRSS1 | |
| SCHEMBL16450812 | 0.86 | F2 (0.75) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL2471251 | 0.85 | F2 (0.72) | F2PLAUST14PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694929-A1 | METHODS FOR TREATING CORNEAL INJURIES | Lin, Sung-Jan (TW) | 2026-02-18 | — | — | EP | claimed |
| WO-2024212857-A1 | METHODS FOR TREATING CORNEAL INJURIES | LIN SUNG JAN (CN) | 2024-10-17 | — | — | WO | claimed |
| EP-3310904-B1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| EP-4694929-A1 | METHODS FOR TREATING CORNEAL INJURIES | Lin, Sung-Jan (TW) | 2026-02-18 | — | — | EP | disclosed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| CN-114929340-B | Methods and agents for glaucoma | 奥夫博医疗创新有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-113164043-B | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024212857-A1 | METHODS FOR TREATING CORNEAL INJURIES | LIN SUNG JAN (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240000849-A1 | MICROFLUIDIC DEVICE FOR ISOLATING COMPONENTS OF BODILY FLUIDS | UNIV CORNELL (US) | 2024-01-04 | — | — | US | disclosed |
| US-11752175-B2 | Compositions and methods for glaucoma | CORNELL UNIVERSITY (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| US-11400106-B2 | Methods for inhibiting microbe growth | MCMASTER UNIVERSITY (CA) | 2022-08-02 | — | — | US | disclosed |
| EP-4031244-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2022-07-27 | — | — | EP | disclosed |
| US-20220211800-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | CORNELL UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211800-A1 | PROCESSES AND AGENTS FOR GLAUCOMA | RHOA, PDE6C, EXOSC10 | F2 3817/4885PLAU 395/4885ST14 4634/4885 |
| US-11400106-B2 | Methods for inhibiting microbe growth | MMP8, BPGM, CAPG | F2 3617/4885PLAU 593/4885ST14 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.